Please sign in to follow a disease.
Chronic idiopathic urticaria
MONDO:0044212Chronic form of idiopathic urticaria.
Also known as: idiopathic urticaria, chronic
75 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New hope for chronic hives: barzolvolimab shows promise in Long-Term trial
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effectiveness of barzolvolimab in adults with chronic spontaneous urticaria (CSU), a condition causing frequent hives and itching. Participants have already completed earlier phase 3 trials. The goal is to see how well the drug control…
Phase: PHASE3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill could offer relief for chronic hives sufferers
Disease control OngoingThis study tests a new daily pill, remibrutinib, for adults with chronic spontaneous urticaria (long-term hives and itching) that antihistamines don't control well. About 470 participants will receive either remibrutinib, a placebo, or an active control (omalizumab injections) fo…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hives drug faces off against xolair in major trial
Disease control OngoingThis study tests a new drug (omalizumab α) against the approved drug Xolair for people with chronic hives that don't get better with antihistamines. About 392 adults aged 15 to 75 will receive either the new drug or Xolair to see how well it reduces itching and hives over 12 week…
Phase: PHASE3 • Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New hope for chronic hive sufferers: drug shows promise in major trial
Disease control OngoingThis study tests a new drug called barzolvolimab for people with chronic spontaneous urticaria (CSU), a condition causing long-term hives and itching that doesn't get better with standard antihistamines. About 963 adults will receive either the drug or a placebo to see if it redu…
Phase: PHASE3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for chronic hives: barzolvolimab in Late-Stage trial
Disease control OngoingThis phase 3 study tests barzolvolimab, a new biologic drug, in 976 adults with chronic spontaneous urticaria (CSU) whose hives and itching persist despite antihistamines. Participants receive either barzolvolimab or a placebo by injection. The main goal is to see if the drug red…
Phase: PHASE3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New pill shows promise for Long-Term relief of chronic hives
Disease control OngoingThis study tests the long-term safety and effectiveness of remibrutinib, a daily pill, for adults with chronic spontaneous urticaria (hives). Participants who completed earlier phase 3 trials will either continue on the drug or switch to placebo to see if symptoms return. The goa…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug shows promise for Long-Term control of chronic hives
Disease control OngoingThis study is testing the long-term safety and effectiveness of a drug called briquilimab for people with chronic hives. It includes 67 participants who have already completed a previous trial with the same drug. The goal is to see if briquilimab remains safe and helps control hi…
Phase: PHASE2 • Sponsor: Jasper Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New shot could tame stubborn hives when other treatments fail
Disease control OngoingThis trial tests a drug called briquilimab for adults with chronic spontaneous urticaria (CSU) — long-lasting hives and itching that don't get better with standard antihistamines or omalizumab. The study has three parts, with some participants getting the drug and others a placeb…
Phase: PHASE1, PHASE2 • Sponsor: Jasper Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Pharmacists take on heart disease: new study tests community-based risk reduction
Disease control OngoingThis study tests whether a pharmacist-led program can help people reduce their risk of heart disease. Over 1,000 adults with conditions like diabetes, high blood pressure, or obesity are taking part. Pharmacists use a step-by-step guide to assess risk and support lifestyle change…
Phase: NA • Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New shot for chronic hives begins safety testing
Disease control OngoingThis early-stage trial tests a single dose of LP-003, a new drug for chronic spontaneous urticaria (long-lasting hives), in 12 healthy adults. The main goal is to check safety and how the body processes the drug. It is not yet tested in people with hives.
Phase: PHASE1 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Could a diet tame chronic hives in children?
Symptom relief ENROLLING_BY_INVITATIONThis trial investigates whether a low-histamine and pseudoallergen-free diet can reduce symptoms like hives and itching in children aged 1 to 18 with chronic spontaneous urticaria. Participants follow the diet for 4 weeks while continuing standard care. Researchers track changes …
Phase: NA • Sponsor: Istanbul University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New hope for chronic hive sufferers: phase 3 drug trial shows promise
Symptom relief OngoingThis study tests a new drug called TLL-018 in 440 adults with moderate-to-severe chronic hives (chronic spontaneous urticaria) that aren't controlled by standard antihistamines. Participants receive either TLL-018 or a placebo for 12 weeks to see if it reduces itching and hives b…
Phase: PHASE3 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New hope for chronic hives? drug tested in small trial
Symptom relief TerminatedThis study tested whether ritlecitinib, a drug already approved for another condition, could safely reduce hives and itching in people with chronic spontaneous urticaria (CSU). The trial planned to enroll adults aged 18–65 who have had hives for over six weeks. Participants would…
Phase: PHASE2 • Sponsor: Ahuva D Cices • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
NIH launches Long-Term observation of inflammatory diseases
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows up to 500 people with acute or chronic inflammatory disorders, such as infections or immune problems, over time. Researchers will monitor participants with standard tests and may screen them for other studies. The goal is to better understand these conditions a…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Scientists hunt for genetic clues in blood and urine to personalize lung cancer care
Knowledge-focused OngoingThis study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biops…
Phase: NA • Sponsor: University of Arkansas • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
15,000 skin patients enrolled in massive Real-World treatment study
Knowledge-focused OngoingThis study follows 15,000 adults and children with skin conditions like eczema, psoriasis, and vitiligo to see how well current and new treatments work in real doctor visits. It does not test a new drug but instead collects information to help doctors understand which treatments …
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Can your diet impact chronic hives? new study investigates
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how diet and oxidative stress (an imbalance of harmful molecules in the body) relate to chronic spontaneous urticaria (CSU), a condition causing itchy hives and swelling. Researchers will compare adults with active CSU to healthy volunteers, tracking their die…
Sponsor: Istanbul Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
AI vs. skin doctors: who diagnoses better?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether artificial intelligence (AI) can match a dermatologist's diagnosis when a general practitioner sends in photos and questions about a patient's skin condition. Researchers will compare the AI's diagnosis to the dermatologist's for about 1000 adults. The…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC